Logo

Lonza Group Closes Acquisition of Cell Research Company Amaxa

Jul 03, 2008
NEW YORK (GenomeWeb News) – Swiss biopharmaceutical research supply company Lonza Group has closed its acquisition of Amaxa, a provider of cell research and transfection technologies, for an undisclosed sum.
 
Lonza sells products for cell-based research, cell therapy manufacturing, and other ingredients for the chemical and biotech markets. The firm, which first agreed to the deal in late May, said it plans to begin integrating Amaxa, including its 160 employees, into its operations immediately.
 
Amaxa offers technologies for use in gene transfer, gene silencing, and gene-based medicine, and a method for transferring DNA or siRNA directly into the nucleus of primary cells and cell lines.
 
Lonza said in May that the purchase will enhance profit margins and growth for the Lonza Bioscience division.

Breaking News
The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.